Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Torsten Steinbrunn, Arnold Bolomsky, Ryosuke Shirasaki, Omar Al-Odat, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Oliver Bohorquez, Brian Glassner, Eleni Anastasakou, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Ricardo De Matos Simoes, James Christensen, Ryan Young, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 327.

https://doi.org/10.1182/blood-2025-327

Published: 2025

Journal Articles

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Huihui Tang, Ricardo De Matos Simoes, Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Eleni Anastasakou, Oliver Bohorquez, Shizuka Yamano, Evangelos Papadopoulos, Lisa Leypoldt, Arun Wiita, Olwyn Mahon, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 2173.

https://doi.org/10.1182/blood-2025-2173

Published: 2025

Journal Articles

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Olga Dashevsky, Ricardo De Matos Simoes, Huihui Tang, Torsten Steinbrunn, Shizuka Yamano, Eleni Anastasakou, Benjamin Barwick, Sara Gandolfi, Ryosuke Shirasaki, Vikas Gupta, Michal Sheffer, Jonathan Licht, Lawrence Boise, Matthew Oser, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 688.

https://doi.org/10.1182/blood-2025-688

Published: 2025

Journal Articles

Functional Genomics Studies Decipher the Genetic Perturbations and Unravel Mechanisms of Response/Resistance upon Mutant-Specific KRAS Inhibition in Multiple Myeloma

Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Phaik Ju Teoh, Lisa Leypoldt, Brian Glassner, Ricardo De Matos Simoes, James Christensen, Constantine S Mitsiades

Blood (2024) 144 (Supplement 1): 3286.

https://doi.org/10.1182/blood-2024-211598

Published: 2024

Journal Articles

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Rin Mizuno, Takeru Sugihara, Phaik Ju Teoh, Lisa B Leypoldt, Mariko Kaji, Jeffrey Sorrell, Brian J Glassner, Ricardo De Matos Simoes, James Christensen, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 4186.

https://doi.org/10.1182/blood-2023-182476

Published: 2023

Journal Articles

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

Olga Dashevsky, Sara Gandolfi, Olli Dufva, Ricardo De Matos Simoes, Jani Huuhtanen, Benjamin G. Barwick, Ryosuke Shirasaki, Michal Sheffer, Aidan Culhane, Jonathan D. Licht, Christine-Ivy Liacos, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Lawrence H. Boise, Francisca Vazquez, Matti Kankainen, Satu Mustjoki, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 6842.

https://doi.org/10.1182/blood-2023-189570

Published: 2023

Journal Articles

Integrated Molecular Landscape of Lesions in Cereblon and Its Pathway in Myeloma Patients: Insights into Mechanisms of Relapse from IMiD-Based Treatments

Lisa B Leypoldt, Torsten Steinbrunn, Phaik Ju Teoh, Ricardo De Matos Simoes, Ryosuke Shirasaki, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 3321.

https://doi.org/10.1182/blood-2023-180033

Published: 2023

Journal Articles

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Blood (2022) 140 (Supplement 1): 8343–8344.

https://doi.org/10.1182/blood-2022-167535

Published: 2022

Journal Articles

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Zuzana Chyra, Mehmet K. Samur, Anil Aktas-Samur, Yao Yao, Sanika Derebail, Tommaso Perini, Yan Xu, Eugenio Morelli, Sophia Adamia, Woojun D Park, Lin Charles, Ryosuke Shirasaki, Masood A. Shammas, Constantine S. Mitsiades, Roman Hajek, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2021-152121

Published: 2021

Journal Articles

Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability

Yao Yao, Woojun D Park, Eugenio Morelli, Mehmet K. Samur, Nicholas P Kwiatkowski, Ryosuke Shirasaki, Yan Xu, Chandraditya Chakraborty, Behnam Nabet, Marta Chesi, Nathaniel Gray, Richard A. Young, Kenneth C. Anderson, Constantine S. Mitsiades, Lin Charles, Nikhil C. Munshi, Mariateresa Fulciniti

Blood (2021) 138 (Supplement 1): 2687.

https://doi.org/10.1182/blood-2021-153469

Published: 2021

Journal Articles

Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma

Olga Dashevsky, Ricardo De Matos Simoes, Benjamin G Barwick, Sara Gandolfi, Ryosuke Shirasaki, Michal Sheffer, Aedin Culhane, Richard WJ Groen, Aviad Tsherniak, Francisca Vazquez, Jonathan D. Licht, Lawrence H. Boise, Constantine S. Mitsiades

Blood (2021) 138 (Supplement 1): 1612.

https://doi.org/10.1182/blood-2021-153870

Published: 2021

Journal Articles

Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma

Ricardo De Matos Simoes, Benjamin G Barwick, Ryosuke Shirasaki, Olga Dashevsky, Sara Gandolfi, Huihui Tang, Brian Glassner, Richard W.J. Groen, Daniel Auclair, Aedin Culhane, Aviad Tsherniak, Francisca Vazquez, Jonathan D. Licht, Lawrence H. Boise, Constantine S. Mitsiades

Blood (2021) 138 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2021-154359

Published: 2021

Journal Articles

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Vikas A. Gupta, Benjamin G. Barwick, Shannon M. Matulis, Ryosuke Shirasaki, David L. Jaye, Jonathan J. Keats, Benjamin Oberlton, Nisha S. Joseph, Craig C. Hofmeister, Leonard T. Heffner, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Constantine S. Mitsiades, Jonathan L. Kaufman, Lawrence H. Boise

Blood (2021) 137 (26): 3604–3615.

https://doi.org/10.1182/blood.2020007899

Published: 2021

Includes: Supplemental data

Journal Articles

Interactions with a "Humanized" Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications

Ryosuke Shirasaki, MD PhD, Sondra L. Downey-Kopyscinski, PhD, Ricardo De Matos Simoes, PhD, Olga Dashevsky, Sara Gandolfi, MD, Megan Bariteau, BSc, Aviad Tsherniak, PhD, Francisca Vazquez, PhD, Maria Themeli, MD PhD, Jonathan D. Licht, MD, Larry H. Boise, PhD, Richard W.J. Groen, PhD, Constantine S. Mitsiades, MD PhD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-143151

Published: 2020

Journal Articles

Functional Genomic Characterization of Endoplasmic Reticulum-Associated Dependencies in Multiple Myeloma - Biologic and Therapeutic Implications

Ryosuke Shirasaki, MD PhD, Ricardo De Matos Simoes, PhD, Shizuka Yamano, Sondra L. Downey-Kopyscinski, PhD, Brian Glassner, PhD, Huihui Tang, PhD, Vikas Gupta, MD PhD, Aviad Tsherniak, PhD, Francisca Vazquez, PhD, Jonathan D. Licht, MD, Larry H. Boise, PhD, Constantine S. Mitsiades, MD PhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-143117

Published: 2020

Journal Articles

Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

Olga Dashevsky, PhD, Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD, Michal Sheffer, PhD, Eugen Dhimolea, PhD, Sara Gandolfi, MD, Huihui Tang, PhD, Sondra L. Downey-Kopyscinski, PhD, Megan Bariteau, B.Sc., Jeffrey Sorrell, BA, Brian Glassner, PhD, John Doench, PhD, Larry H. Boise, PhD, Jonathan D. Licht, MD, Aedin Culhane, PhD, William C. Hahn, MD PhD, Francisca Vazquez, PhD, Aviad Tsherniak, PhD, Constantine S. Mitsiades, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-142651

Published: 2020

Journal Articles

Mechanisms Regulating Myeloma Cell Responsiveness to Antisense Oligonucleotides Targeting IRF4

Ryosuke Shirasaki, MD PhD, Esperanza M Algarín, PhD, Ricardo De Matos Simoes, PhD, Sondra L. Downey-Kopyscinski, PhD, Shizuka Yamano, Xiaolin Luo, Youngsoo Kim, PhD, Robert MacLeod, Constantine S. Mitsiades, MD PhD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-142518

Published: 2020

Journal Articles

POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-142580

Published: 2020

Journal Articles

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Sara Gandolfi, MD, Michal Sheffer, PhD, Olli Dufva, Khalid Saeed, Emily Lowry, Olga Dashevsky, PhD, Ryosuke Shirasaki, MD PhD, Ricardo De Matos Simoes, PhD, Jennifer Roth, Rizwan Romee, MD PhD, Satu Mustjoki, MD PhD, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 620.

https://doi.org/10.1182/blood-2019-130793

Published: 2019

Journal Articles

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

Blood (2019) 134 (Supplement_1): 4407.

https://doi.org/10.1182/blood-2019-130901

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Functional Genomics Studies Decipher the Genetic Perturbations and Unravel Mechanisms of Response/Resistance upon Mutant-Specific KRAS Inhibition in Multiple Myeloma

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

Integrated Molecular Landscape of Lesions in Cereblon and Its Pathway in Myeloma Patients: Insights into Mechanisms of Relapse from IMiD-Based Treatments

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability

Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma

Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Interactions with a "Humanized" Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications

Functional Genomic Characterization of Endoplasmic Reticulum-Associated Dependencies in Multiple Myeloma - Biologic and Therapeutic Implications

Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

Mechanisms Regulating Myeloma Cell Responsiveness to Antisense Oligonucleotides Targeting IRF4

POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only